Retinal Vein Occlusion Treatment Market Report 2026

The retinal vein occlusion treatment market size has grown strongly in recent years. It will grow from $2.42 billion in 2025 to $2.59 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to increasing incidence of retinal vascular diseases, wider clinical acceptance of anti-vegf drugs, expansion of outpatient ophthalmic services, growing clinical trial activity, improved reimbursement coverage.

The retinal vein occlusion treatment market size is expected to see strong growth in the next few years. It will grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing demand for durable treatment outcomes, rising investments in novel drug delivery systems, expansion of biosimilar adoption, growing focus on patient-centric treatment models, increasing use of real-world evidence in therapy selection. Major trends in the forecast period include increasing use of combination drug therapies, rising adoption of long-acting injectables, growing integration of precision diagnostics, expansion of personalized treatment protocols, enhanced focus on visual acuity preservation.

The growing prevalence of eye conditions is anticipated to drive the expansion of the retinal vein occlusion treatment market in the coming years. Eye conditions encompass a wide range of disorders that affect the eyes or vision, ranging from minor irritations and infections to serious diseases such as glaucoma, cataracts, age-related macular degeneration, and diabetic retinopathy. The increase in eye-related conditions is largely attributed to aging populations and the rising incidence of diabetes and hypertension. Treatments for retinal vein occlusion are designed to restore blood flow, reduce inflammation, and prevent vision loss while managing complications associated with this condition. For example, in January 2024, according to the Centers for Disease Control and Prevention, a US-based public health organization, more than 3.4 million Americans aged 40 years and older were blind or visually impaired, a figure projected to double by 2030. Therefore, the increasing prevalence of eye conditions is fueling the growth of the retinal vein occlusion treatment market.

Major companies operating in the retinal vein occlusion treatment market are concentrating on the development of innovative therapies, such as interchangeable biosimilars, to broaden treatment options and improve patient access. Interchangeable biosimilars are biologic medicines that are highly similar to approved reference biologics and can be substituted to effectively manage inflammation and fluid leakage associated with retinal vein occlusion. For instance, in May 2024, Biocon Biologics Limited, an India-based biosimilar manufacturer, received approval from the US Food and Drug Administration for Yesafili (aflibercept-jbvf), an interchangeable biosimilar of EYLEA (aflibercept). Yesafili acts as a vascular endothelial growth factor (VEGF) inhibitor and is indicated for the treatment of several ophthalmic conditions, including neovascular age-related macular degeneration, macular edema following branch or central retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization.

In December 2024, Regeneron Pharmaceuticals, a US-based company specializing in biologic therapies and advanced ophthalmology treatments, acquired Oxular Limited for an undisclosed amount. Through this acquisition, Regeneron aims to strengthen its retinal disease pipeline and enhance its technological capabilities by integrating Oxular’s sustained-delivery therapeutic platform for the treatment of conditions such as diabetic macular edema, retinal vein occlusion, and uveitis. Oxular Limited is a UK-based company developing long-acting ophthalmic drug candidates and proprietary suprachoroidal drug delivery systems designed to improve durability and clinical outcomes in posterior segment eye diseases.

Major companies operating in the retinal vein occlusion treatment market are Roche Holding AG, Bayer AG, Novartis International AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co Ltd, Chengdu Kanghong Pharmaceutical Group Co Ltd, Genentech Inc, Apellis Pharmaceuticals Inc, Alimera Sciences Inc, Ocular Therapeutix Inc, EyePoint Pharmaceuticals Inc, Aerpio Pharmaceuticals Inc, REGENXBIO Inc, Adverum Biotechnologies Inc, Graybug Vision Inc, Oxurion NV, PanOptica Inc, Clearside Biomedical Inc, Kodiak Sciences Inc, Outlook Therapeutics Inc, Annexin Pharmaceuticals AB.

North America was the largest region in the retinal vein occlusion treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal vein occlusion treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the retinal vein occlusion treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the retinal vein occlusion treatment market by increasing the cost of imported pharmaceuticals, injectable delivery systems, diagnostic devices, and laser treatment equipment. Hospitals and specialty clinics in developed regions such as North America and Europe are most affected due to dependence on imported branded therapies and devices, while emerging markets face affordability challenges. These tariffs are raising overall treatment expenses and influencing therapy selection. However, they are also driving local drug manufacturing, encouraging biosimilar development, and strengthening regional supply chains for ophthalmic treatments.

The retinal vein occlusion treatment market research report is one of a series of new reports that provides retinal vein occlusion treatment market statistics, including retinal vein occlusion treatment industry global market size, regional shares, competitors with a retinal vein occlusion treatment market share, detailed retinal vein occlusion treatment market segments, market trends and opportunities, and any further data you may need to thrive in the retinal vein occlusion treatment industry. This retinal vein occlusion treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Retinal vein occlusion (RVO) treatment involves a range of approaches focused on managing complications resulting from blocked blood vessels in the retina. These treatments primarily aim to reduce swelling (edema) and prevent further deterioration of vision.

The main diseases addressed in retinal vein occlusion treatment include central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). Central retinal vein occlusion (CRVO) occurs when the central vein in the retina becomes blocked, causing vision impairment due to reduced blood flow and possible retinal damage. Diagnosis typically involves optical coherence tomography, fundoscopic examination, and fluorescein angiography. Treatment options include anti-vascular endothelial growth factor (anti-VEGF) therapies, corticosteroid medications, and others. These treatments are provided by end users such as hospitals, clinics, research institutions, academic facilities, and other healthcare settings.

The retinal vein occlusion treatment market consists of revenues earned by entities by providing services such as laser therapy, medication administration, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinal vein occlusion treatment market also includes sales of vitrectomy equipment, and optical coherence tomography (OCT) devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.